TPX2 and neoplasm: Importantly, high TPX2 mRNA levels within the patients ́ tumour tissue conferred significantly decreased DFS and OS times in the aG patients (DFS 9.6 vs 25.1 months, HR 4.89, 95% CI 2.38–10.07, P < 0.001; OS 16.4 vs 66.9 months, HR 4.10, 95% CI 1.69–9.97, P < 0.001, Fig. 3e, f), but not in the naG patients (DFS 7.5 vs 13.0 months, HR 1.64, 95% CI 0.37–3.08, P = 0.12; OS 21.7 vs 30.0 months, HR 1.94, 95% CI 0.93–4.08, P = 0.07, Fig. 3g, h).